Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial

Oruka Therapeutics reported positive Week 16 results from its ongoing EVERLAST-B trial of ORKA-001, a biologic candidate for moderate-to-severe plaque psoriasis. The company said the findings mark a clinical milestone as it develops extended half-life monoclonal antibodies intended to combine high efficacy with infrequent dosing. Oruka had planned a conference call to discuss the results; the article provides no specific efficacy figures or stock-price impact.